Atea Pharmaceuticals Inc
Research Atea Pharmaceuticals Inc (AVIR) on Bullrun: market cap USD 413.05M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVIR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 413.05M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 32.93M
- Free cash flow-USD 37.08M
Valuation Snapshot
latest market cap is USD 413.05M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 158.00M | -USD 132.03M | n/a | -1.94 | USD 95.71M | USD 843.00K | USD 275.43M |
| FY2024 | USD 0 | -USD 168.00M | -USD 135.50M | n/a | -2 | USD 64.70M | USD 1.64M | USD 438.87M |
| FY2023 | USD 0 | -USD 136.00M | -USD 85.40M | n/a | -1.63 | USD 143.82M | USD 2.40M | USD 555.19M |
| FY2022 | USD 0 | -USD 116.00M | -USD 122.93M | n/a | -1.39 | USD 188.46M | USD 3.12M | USD 640.57M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 413.05M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 278.91M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 282.95M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 254.48M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 400.61M | 13.0 | n/a | n/a |
| 2021 | 2021-12-31 | USD 742.94M | 6.5 | n/a | n/a |
About Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Atea Pharmaceuticals Inc's market cap?
Atea Pharmaceuticals Inc's market capitalization is USD 413.05M.
What does Atea Pharmaceuticals Inc do?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection.